Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial

被引：0
|
作者：
Sciurba, F. C. [1 ]
Rheault, T. [2 ]
Bengtsson, T. [3 ]
Rickard, K. [2 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Verona Pharma Plc, Raleigh, NC USA
[3] Stat Mind AB, Lund, Sweden
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5007
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Late Breaking Abstract-RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study
    Maurer, Brian
    Singh, Dave
    Martinez, Fernando
    Newman, Kenneth
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [42] Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)
    Kavanaugh, A.
    Mease, P.
    Adebajo, A.
    Wollenhaupt, J.
    Hu, A.
    Shah, K.
    Stevens, R.
    Gomez-Reino, J.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 131 - 131
  • [43] Two-year safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Results from a phase 3, randomized, controlled trial (ESTEEM 1)
    Papp, Kim A.
    Reich, Kristian
    Sobell, Jeffrey M.
    Menter, Alan
    Lacour, Jean-Philippe
    Chimenti, Sergio
    Hu, ChiaChi
    Day, Robert M.
    Shah, Kamal
    Griffiths, Christopher E. M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB256 - AB256
  • [44] SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR DATA FROM MEASURE 1, A PHASE 3 RANDOMISED TRIAL
    Emery, P.
    Baeten, D.
    Deodhar, A.
    Wei, A.
    Geusens, P.
    Talloczy, Z.
    Gong, Y.
    Porter, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 818 - 818
  • [45] LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
    Singh, Dave
    Abbott-Banner, Katharine
    Newman, Kenneth
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [46] Sutimlimab, a complement C1s inhibitor, improves quality of life in patients with cold agglutinin disease: Patient-reported outcomes results of the phase 3 cardinal study
    Roeth, A.
    Barcellini, W.
    Tvedt, Anderson T. H.
    Miyakawa, Y.
    Kuter, D. J.
    Hobbs, W.
    Su, J.
    Jiang, X.
    Arias, Morales J.
    Weitz, I. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 179 - 180
  • [47] SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IMPROVES QUALITY OF LIFE IN PATIENTS WITH COLD AGGLUTININ DISEASE: PATIENT-REPORTED OUTCOMES RESULTS OF THE PHASE 3 CARDINAL STUDY
    Barcellini, W.
    Roth, A.
    Tvedt, T. H. Anderson
    Miyakawa, Y.
    Kuter, D. J.
    Hobbs, W.
    Su, J.
    Jiang, X.
    Morales Arias, J.
    Weitz, I. C.
    HAEMATOLOGICA, 2021, 106 (10) : 111 - 112
  • [48] Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial
    Leavitt, Andrew D.
    Mahlangu, Johnny
    Raheja, Priyanka
    Symington, Emily
    V. Quon, Doris
    Giermasz, Adam
    Fernandez, Maria Fernanda Lopez
    Kenet, Gili
    Lowe, Gillian
    Key, Nigel S.
    Millar, Carolyn M.
    Pipe, Steven W.
    Madan, Bella
    Chou, Sheng-Chieh
    Klamroth, Robert
    Mason, Jane
    Chambost, Herve
    Peyvandi, Flora
    Majerus, Elaine
    Pepperell, Dominic
    Rivat, Christine
    Yu, Hua
    Robinson, Tara M.
    Ozelo, Margareth C.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (08)
  • [49] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial
    Wells, Alvin
    Adebajo, Adewale O.
    Aelion, Jacob A.
    Bird, Paul
    Kivitz, Alan
    Liote, Frederic
    Sarzi-Puttini, Piercarlo
    Hu, ChiaChi
    Stevens, Randall M.
    Edwards, Christopher J.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S680 - S680
  • [50] Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
    Simpson, Eric L.
    Silverberg, Jonathan I.
    Worm, Margitta
    Honari, Golara
    Masuda, Koji
    Sygu, Ewa
    Schuttelaar, Marie L. A.
    Mortensen, Eric
    Laws, Elizabeth
    Akinlade, Bolanle
    Patel, Naimish
    Maloney, Jennifer
    Paleczny, Heather
    Delevry, Dimittri
    Xiao, Jing
    Dubost-Brama, Ariane
    Bansal, Ashish
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (06) : 1190 - 1199
12345